BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update
10 févr. 2020 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference
04 févr. 2020 04h45 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of autologous cellular therapies for highly debilitating neurodegenerative diseases,...
BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®
29 janv. 2020 04h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 29, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit
21 janv. 2020 09h52 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK and LOS ANGELES, Jan. 21, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases,...
BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week
07 janv. 2020 01h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that...
NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue
19 déc. 2019 05h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the...
BrainStorm Issues 2019 Letter to Shareholders
18 déc. 2019 05h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapeutics for neurodegenerative diseases, today issued a Letter to...
BrainStorm Selected as Buzz of BIO 2020 Winner
11 déc. 2019 05h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND
26 nov. 2019 08h05 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
25 nov. 2019 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...